ClinicalTrials.gg
Not yet recruitingNCT07516912feSTIUpdated Apr 8, 2026

Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland

An observational study in HIV (Human Immunodeficiency Virus), Chlamydia and Gonorrhea, sponsored by University of Zurich. Not yet recruiting. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by University of Zurich · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
1,800
Ages
16 Years and older
Sex
All
01

Study summary

The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Counselling and testing can be accessed without participating in the study arm of the project.

02

Conditions studied

  • HIV (Human Immunodeficiency Virus)
  • Chlamydia
  • Gonorrhea
  • Syphilis
  • HCV

Keywords

  • Voluntary counselling and testing
  • sexually transmitted infections
  • HIV
  • implementation of free testing
  • barriers to care
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,035 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 306 are open to participants now.

This study's planned enrollment of 1,800 is above the median of 287 across 503 observational studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

University of Zurich is the lead sponsor of 1,049 studies on the registry; 133 are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

People living in the cities of Lucerne and Zurich, and fullfilling the eligibility criterias of the city programmes either in age or level of income.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • taking part in the pilot programmes
  • understand the study information
  • 16 years of age or older

Exclusion criteria

Exclusion Criteria:

  • not eligible for the pilot programmes
  • not understanding the study information
  • less than 16 years old
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
1,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants in municipal free HIV and STI counselling and testing pilot programmes

    Participants are people accessing the municipal free HIV and STI counselling and testing pilot programmes. People can be eligible by age or low income.

06

What researchers measure

Primary outcomes

  1. Participants' satisfaction (study-specific satisfaction scale)

    Participants' satisfaction is measured as the proportion of participants who "agree" or "strongly agree" with satisfaction statements in the post-visit questionnaire. 5-point Likert scale (1 = strongly disagree, 5 = strongly agree); higher scores indicate greater agreement, thus higher satisfaction.

    Time frame: 3 years

Secondary outcomes

  1. Service capacity/utilisation

    Number of completed voluntary counselling and testing visits recorded per month across participating sites.

    Time frame: 3 years

  2. Access timeliness

    Median number of days between booking date and appointment date for VCT visits

    Time frame: 3 years

  3. Workload healthcare providers

    Healthcare provider workload assessed via a short survey measuring perceived workload and time burden, assessed using a standardised Likert-type scale (1-5); higher scores indicate greater perceived workload.

    Time frame: 3 years

  4. Count diagnosed HIV/STI cases

    Number of newly diagnosed HIV and STI cases identified through the free voluntary counselling and testing visits across participating sites per reporting period.

    Time frame: 3 years

  5. Number of treated STI cases

    Number of participants who received an STI or HIV diagnosis during the pilot project and subsequently received treatment, defined as antibiotics dispensed at a pharmacy or attendance at a medical appointment at Maihof Praxis Lucerne or Checkpoint Zurich.

    Time frame: 3 years

  6. Participants' perception of comfort regarding sexual health

    Participant-reported comfort regarding sexual health (encompassing physical, emotional, and social wellbeing related to sexuality and relationships), measured on a visual analogue scale from 0 (not comfortable) to 100 (very comfortable). Filled in at clinic while waiting for appointment and again approximately 1 week after the appointment.

    Time frame: 3 years

  7. Testing behaviour

    Testing behaviour assessed via administrative data and self-report. Participants indicate whether this is their first STI/HIV test and, for HIV testing, time since last HIV test. Trends in testing frequency are monitored over the study period.

    Time frame: 3 years

  8. Changes in sexual health topics familiarity

    Participants rate 12 topics on a scale from 1 to 5 (1=never heard of it, 5=very familiar); higher scores indicate greater knowledge. Participants rate their familiarity at the clinic prior to the appointment and approximately 1 week after the appointment. The measure is the change between pre- and post-appointment rating.

    Time frame: 3 years

  9. Changes in sexual health knowledge

    Knowledge assessed using 8 true/false items (total score range: 0-8), administered at the clinic prior to the appointment and again approximately one week post-appointment. Higher scores indicate greater knowledge. The measure is the change in score from pre- to post-appointment.

    Time frame: 3 years

  10. Changes in self-efficacy/attitudes

    Self-efficacy and attitudes assessed using 13 items rated on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree), administered at the clinic prior to the appointment and again approximately one week post-appointment. Higher scores indicate greater self-efficacy and more positive attitudes. The measure is the change in score from pre- to post-appointment.

    Time frame: 3 years

  11. Information-seeking behaviour

    Information-seeking behaviour is assessed using a multiple-choice question identifying sources of sexual health information (e.g., internet, healthcare provider, peers). Reported descriptively as frequency and distribution of sources selected; administered at the clinic prior to the appointment only.

    Time frame: 3 years

  12. Proportion of low-income eligible participants

    Proportion of participants holding a KulturLegi card (indicating low-income eligibility) among all enrolled participants; reported descriptively.

    Time frame: 3 years

  13. Reach Among Low-Income Eligible Population

    Proportion of KulturLegi card holders enrolled in the study relative to the total number of KulturLegi cards issued in the catchment area during the study period. Assessed by comparing observed reach against a pre-specified target of ≥5% of the eligible low-income population.

    Time frame: 3 years

  14. Comparative Outcomes by Eligibility Group

    STI/HIV positivity rates, re-testing rates, and knowledge scores compared between low-income eligible participants (KulturLegi card holders) and age-eligible participants. Differences between groups are reported descriptively; regression modelling may be applied to explore associations and inform policy decisions.

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared. Access to data is restricted to authorised project personnel. For data sharing partcipant consenst needs to be sought.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07516912
Collaborators
Checkpoint Zurich, Checkpoint Lucerne, Test-In Zurich
Responsible party
Andrea Farnham (PhD, University of Zurich) — Principal investigator
First posted
Apr 8, 2026
Start date
Apr 7, 2026 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Apr 8, 2026

Study contacts

Andrea C Farnham, PhD
Contact
testi@ebpi.uzh.ch
+41 44 634 60 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion